National Institutes of Health to Grant Exclusive Patent License for Anti-CD19 CAR Treatment

Summary

The National Institutes of Health is considering granting an exclusive patent license to Sangamo BioSciences, Inc. for the development of an anti-CD19 chimeric antigen receptor (CAR) for treating human cancers, in accordance with US patent laws.